We are revolutionizing the translational potential of animal models in preclinical research. Discover the latest articles and news about our recent activities.
19 December 2024
The rapid growth of RNA therapeutics, including siRNA and mRNA, is transforming the pharmaceutical and medical landscape, offering unprecedented potential for treating diseases ranging from viral infections to metabolic disorders. Despite this promise, translating these groundbreaking treatments from the lab to the clinic is fraught with challenges.
26 March 2024
Breaking News: Revolutionizing Pharmaceutical Innovation with Japan’s PhoenixBio In the realm of pharmaceutical innovation, a new dawn arises with Japan's PhoenixBio leading the charge. With a groundbreaking article recently published, PhoenixBio introduces cutting-edge human liver models boasting an astonishing 90% and higher human hepatocyte composition, redefining drug testing worldwide while upholding the highest ethical standards.
18 October 2023
The promise of adeno-associated virus (AAV) vector-based gene therapies is undeniable. These therapies have already demonstrated potential in treating conditions like spinal muscular atrophy, retinal dystrophy, and hemophilia B, with the FDA approving three treatments as of early 2023. Yet, despite these successes, many promising therapies fail during clinical trials.
3 January 2022
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries, with an estimated incidence of around 25% worldwide.
1 April 2021
PhoenixBio Co., Ltd. (“PhoenixBio”) announced today that it has entered into an agreement to partner with Inotiv, Inc. (“Inotiv”) in providing pre-clinical research services utilizing the PXB-mouse® (cDNA-uPA/SCID mouse model with a humanized liver).
